Jobevne (bevacizumab-nwgd) vs Zirabev (bevacizumab-bvzr)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Jobevne (bevacizumab-nwgd)

Marketed by Biocon and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Zirabev (bevacizumab-bvzr)

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02364999 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.

Reported efficacy

Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)

Result source: NCT02364999

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJobevne (bevacizumab-nwgd)Zirabev (bevacizumab-bvzr)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999
Duration of response, median—Not reported8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999

PFS, median

Jobevne (bevacizumab-nwgd)
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

OS, median

Jobevne (bevacizumab-nwgd)
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

ORR

Jobevne (bevacizumab-nwgd)
—Not reported
Zirabev (bevacizumab-bvzr)
45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999

Duration of response, median

Jobevne (bevacizumab-nwgd)
—Not reported
Zirabev (bevacizumab-bvzr)
8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Jobevne (bevacizumab-nwgd): no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Jobevne (bevacizumab-nwgd): 0 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZirabev (bevacizumab-bvzr)
Dropout rate
46.1%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
22.8%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
alopecia 46.6%
anaemia 28.7%
fatigue 20.5%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zirabev (bevacizumab-bvzr)

ORR 45.3% (n=358) vs 44.6% (n=361) Bevacizumab-EU @ 25wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 8.38 vs 6.62 Bevacizumab-EU months
time to event · months
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to months from 36.3 weeks as posted
PFS 32.3% (n=358) vs 30.5% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 65.8% (n=358) vs 64.1% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Jobevne (bevacizumab-nwgd)'s landscape · Zirabev (bevacizumab-bvzr)'s landscape